Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis

Published in: Science Advances

Authors: Barry J. Liang(1,2), Sumiao Pang(1), Robert Perttilä(3), Chen-Hua Ma(1), Payal Srivastava(1), Brandon Gaitan(1), Aaron J. Sorrin (1), Nada Fadul(1), Zoe Ylöniemi(3), Dana M. Roque(4,5), Tayyaba Hasan(6), Petteri Uusimaa(3), Huang-Chiao Huang(1,4*)

(1) Fischell Department of Bioengineering, University of Maryland
(2) Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(3) Modulight Corp., Finland
(4) Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine
(5) Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine
(6) Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School


Fluorescence-guided intervention can bolster standard therapies by detecting and treating microscopic tumors before lethal recurrence. Tremendous progress in photoimmunotherapy and nanotechnology has been made to treat metastasis. However, many are lost in translation due to heterogeneous treatment effects. Here, we integrate three technological advances in targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710) to improve photoimmunotherapy. TPMAL consists of a nanoliposome chemotherapy labeled with fluorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy. ML7710 is connected to Modulight Cloud to capture and analyze multispectral emission from TPMAL for fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models. FGDD revealed that TPMAL enhances drug delivery to metastases by 14-fold. ML7710 captured interpatient variability in TPMAL uptake and prompted FGLD in >50% of animals. By combining TPMAL, ML7710, and fluorescence-guided intervention, variation in treatment response was substantially reduced and tumor control improved without side effects.


Read the article here